Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of TAK-536 pediatric formulations vs commercial tablet
jRCT1080222801Phase 1
- Sponsor
- Takeda
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azilsartan medoxomil in hypertension (HTN) (2 arms), sponsored by Takeda. Primary endpoint: Bioequivalence of TAK-536 pediatric formulations vs commercial tablet.
02
Drugs
azilsartan medoxomil
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on jRCT1080222801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080222801.